Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PMN310 in Early Alzheimer's Disease
NCT06750432Phase 1Active, not recruiting
- Sponsor
- ProMIS Neurosciences
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PMN310 in Alzheimer's disease (AD) (3 cohorts), sponsored by ProMIS Neurosciences. Primary endpoints: Safety and tolerability of PMN310 and Biomarker response to PMN310. Started Dec 2024; status: active, not recruiting.
02
Drugs
PMN310
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06750432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06750432.